Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Pharming Group N.V.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-84.5% vs price
Base Case (Median)
-72.7% vs price
Bull Case (75th pct.)
-34.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.05 | -95.1% | High (40%) |
| EV/EBITDA | $0.39 | -64.7% | Medium (20%) |
| EV/FCF | $1.70 | 55.0% | Medium (20%) |
| Earnings Power Value | $0.20 | -81.5% | Medium (50%) |
Based on 4 out of 7 methods, PHGUF appears overvalued at the current price of $1.10. The base case fair value of $0.30 implies 72.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.